Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc. has announced a collaboration with the Global Coalition for Adaptive Research to evaluate its cancer therapy, pelareorep, in an innovative pancreatic cancer trial. This collaboration aims to streamline the pathway for pelareorep’s development, leveraging an adaptive trial design to potentially expedite treatment availability and reduce costs. The promising combination therapy has shown impressive results in earlier studies, increasing the objective response rate in pancreatic cancer patients.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
